JPRN-jRCT2080222078未知1 期
A phase I/II study in combination of YHI-1001 and Sorafenib in patients with advanced hepatocellular carcinoma previously untreated with systemic chemotherapy
试验速览
- 阶段
- 1 期
- 入组人数
- 164
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1)Patients with advanced or metastatic hepatocellular carcinoma
- •(2)Patients with ECOG PS of 0-1
- •(3)Patients who can be treated with oral medications and have no gastrointestinal function disorder which is considered to affect the absorption of medications
排除标准
- •(1)Patients with a history of treatment with HDAC inhibitors
- •(2)Pregnant women and lactating mothers
- •(3)Patients with brain metastases or suspected brain metastases based on the clinical symptoms
研究者
相似试验
未知
1 期
Phase I/II study of YHI-1001 in combination with Docetaxel in patients with advanced, metastatic or recurrent non-small cell lung cancer who have received platinum-based chemotherapyPatients with non-small cell lung cancer who have received platinum-based chemotherapyJPRN-jRCT2080222077Yakult Honsha Co., Ltd.118
未知
1 期
A phase I study of YHI-1001JPRN-jRCT2080221834Yakult Honsha Co., Ltd.18
未知
1 期
Phase I trial of YHI-1003 plus Bortezomib and DexamethasoneRelapsed Multiple Myeloma previously treated with BortezomibJPRN-jRCT2080221706Yakult Honsha Co., Ltd.18
未知
1 期
Phase I trial of YHI-1003relapsed or refractory neuroblastomaJPRN-jRCT2080222084Yakult Honsha Co., Ltd.18
未知
2 期
Phase II trial of YHI-1003JPRN-jRCT2080222238Yakult Honsha Co., Ltd.96